Knight Therapeutics Inc.

TSX:GUD Stock Report

Market Cap: CA$583.8m

Knight Therapeutics Past Earnings Performance

Past criteria checks 0/6

Knight Therapeutics's earnings have been declining at an average annual rate of -45.5%, while the Pharmaceuticals industry saw earnings growing at 31.5% annually. Revenues have been growing at an average rate of 37.9% per year.

Key information

-45.5%

Earnings growth rate

-45.5%

EPS growth rate

Pharmaceuticals Industry Growth23.1%
Revenue growth rate37.9%
Return on equity-2.3%
Net Margin-5.1%
Next Earnings Update09 May 2024

Recent past performance updates

Recent updates

Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

May 28
Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why

May 07
Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why

Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Apr 07
Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares

Mar 20
Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares

If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%

Mar 02
If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%

Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 03
Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?

Jan 19
Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?

What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?

Jan 04
What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?

A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Dec 20
A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares

Dec 07
The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares

What Type Of Returns Would Knight Therapeutics'(TSE:GUD) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Dec 02
What Type Of Returns Would Knight Therapeutics'(TSE:GUD) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Need To Know: The Consensus Just Cut Its Knight Therapeutics Inc. (TSE:GUD) Estimates For 2021

Nov 17
Need To Know: The Consensus Just Cut Its Knight Therapeutics Inc. (TSE:GUD) Estimates For 2021

Revenue & Expenses Breakdown
Beta

How Knight Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TSX:GUD Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 23328-178418
30 Sep 23336-89017
30 Jun 23326-169017
31 Mar 23312-159016
31 Dec 22294-308915
30 Sep 22270-238614
30 Jun 22271-338114
31 Mar 22261-77813
31 Dec 21243167413
30 Sep 21240326813
30 Jun 21212596912
31 Mar 21200476712
31 Dec 20200427112
30 Sep 2018227659
30 Jun 201406537
31 Mar 20908386
31 Dec 194715244
30 Sep 191421173
30 Jun 191337133
31 Mar 191222142
31 Dec 181324122
30 Sep 181131112
30 Jun 181022113
31 Mar 181018123
31 Dec 17917123
30 Sep 17818123
30 Jun 17820122
31 Mar 17724102
31 Dec 16619102
30 Sep 1641691
30 Jun 1631783
31 Mar 1622193
31 Dec 1513493
30 Sep 151154103
30 Jun 15114892
31 Mar 15114071
31 Dec 14012641

Quality Earnings: GUD is currently unprofitable.

Growing Profit Margin: GUD is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: GUD is unprofitable, and losses have increased over the past 5 years at a rate of 45.5% per year.

Accelerating Growth: Unable to compare GUD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GUD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22%).


Return on Equity

High ROE: GUD has a negative Return on Equity (-2.25%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.